Form 4 Filing for Adaptive Biotechnologies Corp

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, reported the sale of 239,351 shares of Common Stock on July 2, 2026, under a Rule 10b5-1 trading plan. The weighted-average sale price was $21.74, with individual sales ranging from $21.15 to $22.145. Following this transaction, Robins owns 1,166,547 shares. Additionally, Robins reported the sale of 146,889 shares of Common Stock on the same date, also under a Rule 10b5-1 trading plan. The weighted-average sale price for this transaction was $22.45, with prices ranging from $22.15 to $22.75. Post-transaction, Robins owns 1,019,658 shares. These transactions were direct holdings.